The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets

Jessica K. Lee; Julia C. F. Quintanilha; Kuei-Ting Chen; Bernard J. Fendler; Candice Francheska B. Tambaoan; Ryon P. Graf; Nicole Odzer; L. Pusztai; Maryam B. Lustberg; Harshabad Singh; Matthew R. Strickland; Tess A. O’Meara; Sara M. Tolaney; Timothy A. Yap; Jeffrey Ross; Amaya Gascó Hernández; Brennan Decker; Richard S.P. Huang; Samuel J. Klempner; Ethan S. Sokol; Alexa B. Schrock

doi:10.1158/1078-0432.ccr-25-4018

Key Points

The study aims to explore the prevalence and variability of copy number amplifications across different tumor types and their implications for clinical outcomes.
Analyzed CN (copy number) amplifications across various genes and tumor types.
Evaluated the AmpRatio, particularly for the ERBB2 gene, in relation to clinical treatment responses.
Assessed the role of CN quantification in making clinical decisions regarding therapies.
Identified diverse biomarkers associated with CN amplifications across tumors.
Demonstrated that ERBB2 AmpRatio correlates with outcomes for HER2-directed therapies.
Highlighted the need for standardized methods in CN quantification for effective patient selection.

Implication

Analysis identifies gene amplifications as biomarkers and ratios impacting treatment outcomes, suggesting new methods for patient selection.

Abstract

CN amplifications are prevalent and diverse biomarkers and AmpRatio is variable across genes and tumor types. ERBB2 AmpRatio is associated with outcomes to HER2-directed therapies and may have utility alongside IHC for clinical decision making. With the increasing number of therapies targeting amplifications/overexpression, it will be important to define harmonized methods for CN quantification for optimal patient selection.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/69c37b81b34aaaeb1a67e0a6 https://doi.org/10.1158/1078-0432.ccr-25-4018

View Full Paper

Ask AI

Bookmark

Share

The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets

Key Points

Implication

Abstract

Discussion

Cite This Study

The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading